# Self-Identification of Generic Drug Facilities, Sites, and Organizations; Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/self-identification-of-generic-drug-facilities-sites-and-organizations-guidance-for-industry/0f6af607-fb4c-4df3-8f72-edf8eeb27fbe

> FDA guidance document: Self-Identification of Generic Drug Facilities, Sites, and Organizations; Guidance for Industry. Issue date: September 23, 2016. Get complete insights and analysis.

---

## Details

- Title: Self-Identification of Generic Drug Facilities, Sites, and Organizations; Guidance for Industry
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2016-09-23
- Last Changed: 2020-04-29
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2012-D-0881">FDA-2012-D-0881</a>

## Related Documents

- [Clinical Pharmacology Labeling for Human Prescription Drug and Biological Products — Content and Format](https://www.globalkeysolutions.net/guidances/guidance-document/clinical-pharmacology-labeling-for-human-prescription-drug-and-biological-products-content-and-format/43229708-ad02-40d3-b318-996c20552a39)
- [Bioanalytical Method Validation Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/bioanalytical-method-validation-guidance-for-industry/2bd6e05d-59f0-445b-b5b1-9e6c4f25eeef)
- [E2C(R2) Periodic Benefit-Risk Evaluation Report – Questions and Answers](https://www.globalkeysolutions.net/guidances/guidance-document/e2cr2-periodic-benefit-risk-evaluation-report-questions-and-answers/9735c0c5-468e-4e9b-a4c9-a7bad1eb9d94)